Prescient Therapeutics (ASX:PTX), a clinical-stage oncology company, has received a cash refund of $3,441,102.65 from the Australian Taxation Office under the Australian Government's Research and Development Tax Incentive for the financial year ended 30 June 2026.

Key Points

  • Prescient Therapeutics received a $3,441,102.65 R&D Tax Incentive refund from the Australian Taxation Office
  • The refund relates to eligible R&D expenditure for the financial year ended 30 June 2026
  • Expenditure was principally on the Phase 2a study of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma (CTCL)
  • The refund is described as non-dilutive funding, adding to the $6 million raised in September/October

R&D Tax Incentive Refund Details

The cash refund of $3,441,102.65 was received from the Australian Taxation Office under the Australian Government's Research and Development Tax Incentive programme. The refund covers eligible research and development expenditure incurred during the financial year ended 30 June 2026. According to the filing, the expenditure related principally to the Phase 2a study of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma. The company described the refund as non-dilutive funding that goes directly into the development of PTX-100.

PTX-100 Phase 2a Study in Cutaneous T-Cell Lymphoma

The Phase 2a study of PTX-100 is a global trial recruiting patients with relapsed or refractory cutaneous T-cell lymphoma. According to the filing, 20 evaluable patients, comprising 10 in each dosing arm, are now enrolled in the study. The first Dose Optimisation Committee review is scheduled to take place in December 2026. The company stated that enrolment continues towards a planned total of 40 evaluable patients. The US FDA has granted PTX-100 Orphan Drug Designation for all T-cell lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides.

Funding Position Following Capital Raise and Refund

The filing states that the R&D Tax Incentive refund adds to $6 million raised in September/October, with both amounts directed toward the continued development of PTX-100. CEO James McDonnell was quoted in the filing stating that the R&D Tax Incentive is non-dilutive funding that goes directly into the development of PTX-100, and that together with the recent capital raise, it strengthens the company's position as it approaches the first Dose Optimisation Committee review in December. The Disclosure Committee of Prescient Therapeutics Limited approved the release of the filing.